Sera Neutralizing Activities Against Severe Acute Respiratory Syndrome Coronavirus 2 and Multiple Variants 6 Months After Hospitalization for Coronavirus Disease 2019
Author(s) -
Maureen Betton,
Marine Livrozet,
Delphine Planas,
Antoine Fayol,
Blandine Monel,
Benoît Védie,
Timothée Bruel,
Éric Tartour,
Nicolas Robillard,
JeanClaude Manuguerra,
Anne Blanchard,
Jade Ghosn,
Benoît Visseaux,
Hélène Péré,
David Lebeaux,
Olivier Schwartz,
David Veyer,
JeanSébastien Hulot,
Laurent Abel,
Claire Andréjak,
François Angoulvant,
Delphine Bachelet,
Krishna Bhavsar,
Lila Bouadma,
Anissa Chair,
Camille Couffignal,
Charlène Da Silveira,
MariePierre Debray,
Diane Descamps,
Xavier Duval,
Philippine Eloy,
Marina EspositoFarèse,
Nadia Ettalhaoui,
Nathalie Gault,
Isabelle Gorenne,
Isabelle Hoffmann,
Ouifiya Kafif,
Sabrina Kali,
Antoine Khalil,
Cédric Laouénan,
Samira Laribi,
Minh Quan Lê,
Quentin Le Hingrat,
François-Xavier Lescure,
Jean Christophe Lucet,
France Mentré,
Jimmy Mullaert,
Nathan PeifferSmadja,
Gilles Peytavin,
Carine Roy,
Marion Schneider,
Nassima Si Mohammed,
Lysa Tagherset,
Coralie Tardivon,
Marie-Capucine Tellier,
JeanFrançois Timsit,
Théo Trioux,
Sarah Tubiana,
Yazdan Yazdanpanah,
Romain Basmaci,
Olivier Picone,
Sylvie Behilill,
Sylvie van der Werf,
Vincent Enouf,
Hugo Mouquet,
Marine Beluze,
Dehbia Benkerrou,
Céline Dorival,
François Téoulé,
Amina Meziane,
François Bompart,
Maude Bouscambert,
Minerva Cervantes-Gonzalez,
Éric D’Ortenzio,
Oriane Puéchal,
Caroline Semaille,
Catherine Chirouze,
Alexandra Coelho,
Sandrine CouffinCadiergues,
Hélène Esperou,
Ikram Houas,
Salma Jaafoura,
Aurélie Papadopoulos,
Dominique Deplanque,
Mathilde Desvallée,
Coralie Khan,
Alpha Diallo,
Marie Bartoli,
Soizic Le Mestre,
Noémie Mercier,
Christelle Paul,
Ventzislava Petrov–Sanchez,
Alphonsine Diouf,
Alexandre Hoctin,
Marina Mambert,
François Dubos,
Manuel Etienne,
Alexandre Gaymard,
Tristan Gigante,
Morgane Gilg,
Bénédicte Rossignol,
Jérémie Guedj,
Hervé Le Nagard,
Guillaume Lingas,
Nadège Néant,
Florentia Kaguelidou,
Justine Pages,
Yves Lévy,
Aurélie Wiedemann,
Claire LévyMarchal,
Bruno Lina,
Manuel RosaCalatrava,
Olivier Terrier,
Denis Malvy,
Marion Noret,
Patrick Rossignol,
Christelle Tual,
Aurélie Veislinger,
Noémie Vanel
Publication year - 2021
Publication title -
clinical infectious diseases
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 3.44
H-Index - 336
eISSN - 1537-6591
pISSN - 1058-4838
DOI - 10.1093/cid/ciab308
Subject(s) - serology , medicine , antibody , neutralizing antibody , immunology , coronavirus , immunoglobulin g , virology , covid-19 , neutralization , disease , infectious disease (medical specialty)
Background Humoral response to severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) occurs within the first weeks after coronavirus disease 2019 (COVID-19). Those antibodies exert a neutralizing activity against SARS-CoV-2, whose evolution over time after COVID-19 as well as efficiency against novel variants are poorly characterized. Methods In this prospective study, sera of 107 patients hospitalized with COVID-19 were collected at 3 and 6 months postinfection. We performed quantitative neutralization experiments on top of high-throughput serological assays evaluating anti-spike (S) and anti-nucleocapsid (NP) immunoglobulin G (IgG). Results Levels of seroneutralization and IgG rates against the ancestral strain decreased significantly over time. After 6 months, 2.8% of the patients had a negative serological status for both anti-S and anti-NP IgG. However, all sera had a persistent and effective neutralizing effect against SARS-CoV-2. IgG levels correlated with seroneutralization, and this correlation was stronger for anti-S than for anti-NP antibodies. The level of seroneutralization quantified at 6 months correlated with markers of initial severity, notably admission to intensive care units and the need for mechanical invasive ventilation. In addition, sera collected at 6 months were tested against multiple SARS-CoV-2 variants and showed efficient neutralizing effects against the D614G, B.1.1.7, and P.1 variants but significantly weaker activity against the B.1.351 variant. Conclusions Decrease in IgG rates and serological assays becoming negative did not imply loss of neutralizing capacity. Our results indicate a sustained humoral response against the ancestral strain and the D614G, B.1.1.7, and P.1 variants for at least 6 months in patients previously hospitalized for COVID-19. A weaker protection was, however, observed for the B.1.351 variant.
Accelerating Research
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom
Address
John Eccles HouseRobert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom